Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Posts Quarterly Earnings Results, Beats Estimates By $405.83 EPS

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) posted its quarterly earnings data on Friday. The company reported ($2.17) EPS for the quarter, beating analysts’ consensus estimates of ($408.00) by $405.83, FiscalAI reports.

Valion Bio, Inc. Common Stock Price Performance

Shares of VBIO traded up $0.02 during trading hours on Friday, hitting $0.19. 169,670,743 shares of the company were exchanged, compared to its average volume of 2,503,005. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.31 and a quick ratio of 3.02. The company has a market capitalization of $790,990.00, a PE ratio of -0.03 and a beta of 1.85. The firm has a fifty day simple moving average of $0.45 and a 200-day simple moving average of $0.78. Valion Bio, Inc. Common Stock has a one year low of $0.16 and a one year high of $5.60.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

About Valion Bio, Inc. Common Stock

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.